MedTrace Logo

Benefits of Jing-Si-Herbal-Tea in Bronchiectasis

NCT06901557 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-03-30

No results posted yet for this study

Summary

Patients are divided into two groups: the usual care group (UC group) and the Jing-Si Herbal Tea group (JSHT group).

* \*\*UC Group\*\*: Receives standard treatment and one placebo packet daily for three months.
* \*\*JSHT Group\*\*: Receives standard treatment plus one packet of Jing-Si Herbal Tea daily for three months.

Each group includes 30 participants. The study runs from January 1, 2014, to December 31, 2014. Exclusions include severe liver or renal dysfunction and allergy to Jing-Si Herbal Tea. Participants must follow the study protocol.

\*\*Assessments\*\*:

* \*\*HRQL\*\*: Measured using the COPD Assessment Test (CAT) and the Modified Medical Research Council (mMRC) scale.
* \*\*Blood Tests\*\*: Include WBCs, hemoglobin, hematocrit, platelets, BUN, creatinine, uric acid, liver enzymes, electrolytes, CRP, and pPro-BNP. Blood samples will also be analyzed for DAMPs and inflammatory cytokines.
* \*\*Pulmonary Function Tests (PFT)\*\*: Conducted with a spirometer per American Thoracic Society guidelines.

Conditions

Interventions

COMBINATION_PRODUCT

Jing-Si Herbal Tea

The JSHT group will receive the standard medical treatment along with Jing-Si Herbal Tea, one packet daily for three months.

COMBINATION_PRODUCT

Placebo

The UC group will receive standard medical treatment, with one placebo packet daily for three months.

Sponsors & Collaborators

  • Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06901557 on ClinicalTrials.gov